Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$51.76 USD

51.76
1,723,425

+2.06 (4.14%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $51.66 -0.10 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

by Zacks Equity Research

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.51, moving +1.43% from the previous trading session.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $48.81, denoting a +2.61% move from the preceding trading day.

Zacks Equity Research

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?

by Kinjel Shah

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $46.93, representing a -1.59% change from its previous close.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.69, representing a -4.79% change from its previous close.

Zacks Equity Research

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.